India is grappling with a substantial burden of diabetes-related complications with diabetic peripheral neuropathy being a ...

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to ...

Alkem Laboratories partners with Sonnet BioTherapeutics to develop and commercialize SON-080, a potential treatment for ...

Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet ...

The drug is expected to offer nerve regeneration, potentially modifying the disease in diabetic peripheral neuropathy ...

Advantage Neuropathy specializes in providing leading edge pain therapy and treatment that is an FDA cleared solution.

Sonnet BioTherapeutics Holdings, Inc. (SONN) announced Wednesday that it has entered into a licensing agreement with Alkem ...

Alkem Laboratories said that it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, to develop, manufacture and commercialise the drug candidate 'SON-080' for the ...

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate SON-080 for the ...

[4,5,6] Only a few patients had signs or symptoms of neuropathy ... producing liver dysfunction can independently cause peripheral neuropathy. Hence, a cause and effect relationship between ...

Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an update. Sonnet BioTherapeutics Holdings, Inc. has partnered with ...